Back
CT.gov ↗CT.gov ↗CT.gov ↗8-K ↗
AXSM
Axsome Therapeutics, Inc.
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on central nervous system conditions with three FDA-approved commercial products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine treatment. The company develops small molecules targeting novel mechanisms of action to address unmet needs in CNS indications.
$207.75+85.01%1Y
AXSM · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Fibromyalgia
Phase 3Binge-Eating Disorder
Phase 3Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Phase 3Excessive Sleepiness
Phase 3Shift-work Disorder
Phase 3Binge-Eating Disorder
Phase 3Excessive Sleepiness
Phase 3Shift-work Disorder
UnknownIndication pending review
Unknownnarcolepsy
UnknownIndication pending review
Catalyst Calendar
DEC
ReadoutSolriamfetol 150 mg
“A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder — primary completion 2026-12”
MAR
ReadoutAXS-14 (Esreboxetine)
“A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia — primary completion 2028-03”
DEC
ReadoutSolriamfetol 150 mg
“A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms — primary completion 2028-12”
Past (1)
DEC 31
NDAAXS-12
“the Company issued a press release announcing that it had received formal pre-New Drug Application ("NDA") meeting minutes from the FDA for its planned NDA submission for AXS-12 in narcolepsy”